India's leading pharmaceutical company, Intas Pharmaceuticals Limited, is taking a step toward making therapy for chronic immune thrombocytopenia (ITP) more affordable to patients by being the first to launch Romiplostim in India under the brand name Romy. With the launch of Romiplostim, cost for treating chronic ITP will come down by almost six times. Intas' biosimilars are manufactured at the company's biotechnology plant in Moraiya in Gujarat. Industrial Info is tracking Intas' manufacturing assets involving oral formulations, injectables and active pharmaceutical ingredients (API) units. Industrial Info database has 831 Pharma-Biotech plant records in India, with more then 3,500 functional management contacts. Click here for a list.
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×For More Info!
